search
Back to results

Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents

Primary Purpose

Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.

Status
Available
Phase
Locations
China
Study Type
Expanded Access
Intervention
human whole exome
whole genomic
Sponsored by
Xiaofan Zhu
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an expanded access trial for Fanconi Anemia focused on measuring fanconi anemia, hematopoiesis maintainance

Eligibility Criteria

1 Month - 18 Years (Child, Adult)All Sexes

Inclusion Criteria:

All the children that are diagnosed to be FA patients at the Blood Disease Hospital between 08/01/2010 - 07/31/2011, will be asked to participated in this study after acquiring the consent.

Exclusion Criteria:

Can not acquiring content

Sites / Locations

  • Institute of Hematology & Blood Diseases Hospital

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

First Posted
November 21, 2013
Last Updated
November 21, 2013
Sponsor
Xiaofan Zhu
search

1. Study Identification

Unique Protocol Identification Number
NCT01995305
Brief Title
Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
Official Title
Exome Sequencing of Fanconi Anemia Children and the Their Parents
Study Type
Expanded Access

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Xiaofan Zhu

4. Oversight

5. Study Description

Brief Summary
Fanconi anemia is a rare autosomal or sex linked recessive genetic disease. The disease is characterized by bone marrow hematopoiesis failure, multiple congenital abnormalities, and susceptibility to neoplastic diseases. The cells of FA patients are extremely sensitive to MMC and DEB. The symptoms and ages of FA patients are different, so by comparing the exome of FA patients and their parents, the mutations that were accumulated in FA patients could be found, and these genes might be sensitive to repairment and be important for hematopoiesis maintainance.
Detailed Description
Heterogeneity of FA. In the research of animal model, the phenotypes of FANCA, FANCC and FANCG knockout mice are similar. They grow up and develop normally, without any severe blood disease or tumor. However, they show chromosome instablity and highly sensitivity to MMC. And they have gonadal dysfunction and fertility defects. From this we conclude that the severe physical deformity of FA patients might be induced by other mutations. By comparing among the FA patients and between FA patiens and normal people, we look forward to find the mutated genes and verify their relationship with the physical deformity. Even in 90% of FA patients the bone marrow failure will eventually occur, but the starting age ranges from 8-84. And Immuno-inhibition therapy has no effects on FA. Other DNA repair dysfunction diseases have higher rate of tumor, but not so high rate of bone marrow failure as FA does, which implies that the FA protein has the key role in hematopoietic stem cell maintainance. In FancC-/- mice, young mice is insensitive to DNA crosslinks with comet assay, but not adult mice, indicating that the accumulation of DNA damage during time leads to DNA repairment defects. by comparing the exome of FA patients and their parents, the mutations that were accumulated in FA patients could be found, and these genes might be sensitive to repairment and be important for hematopoiesis maintainance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fanconi Anemia, Autosomal or Sex Linked Recessive Genetic Disease, Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases., Hematopoiesis Maintainance.
Keywords
fanconi anemia, hematopoiesis maintainance

7. Study Design

8. Arms, Groups, and Interventions

Intervention Type
Genetic
Intervention Name(s)
human whole exome
Intervention Description
he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
Intervention Type
Genetic
Intervention Name(s)
whole genomic
Other Intervention Name(s)
whole exome
Intervention Description
This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria: All the children that are diagnosed to be FA patients at the Blood Disease Hospital between 08/01/2010 - 07/31/2011, will be asked to participated in this study after acquiring the consent. Exclusion Criteria: Can not acquiring content
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xiaofan Zhu, professor
Phone
+86-022-23909001
Email
zhuxiaof@yahoo.com.cn
First Name & Middle Initial & Last Name or Official Title & Degree
Huimin Zeng, doctor
Phone
+86-022-23909197
Email
zengpretty@yahoo.com.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tao Cheng, professor
Organizational Affiliation
Institute of Hematology & Blood Diseases Hospital, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Institute of Hematology & Blood Diseases Hospital
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300020
Country
China
Individual Site Status
Available
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaofan Zhu, professor
Phone
+86-022-23909001
Email
zhuxiaof@yahoo.com.cn
First Name & Middle Initial & Last Name & Degree
Xiaofan Zhu, professor

12. IPD Sharing Statement

Links:
URL
http://www.rockefeller.edu/fanconi/mutate
Description
informatin about this study

Learn more about this trial

Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents

We'll reach out to this number within 24 hrs